Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Exec Vice President and CMO | January 03, 2017 | January 05, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALPINE IMMUNE SCIENCES, INC.
Report date January 03, 2017 · Filed January 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,368 |
Ending reported balance
After 2017-01-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-01-03 · Exercise / conversion · Acquired 18,055 · Balance 18,055 F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's. Row 2 · 2017-01-04 · Sale · Disposed 6,687 · Balance 11,368 F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 162,501 |
Reported balance
After 2017-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-01-03 · Exercise / conversion · Disposed 18,056 · Balance 162,501 F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issued on settlement of restricted stock units ("RSUs") granted to the reporting person upon vesting of such RSU's.
F2: Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person to cover tax obligations in connection with the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.27 to $2.34, inclusive. The reporting person undertakes to provide Nivalis Therapeutics, Inc., any security holder of Nivalis Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
F4: Represent fully vested RSUs. Each RSU represents the contingent right to receive one share of Common Stock. The RSUs vest in twelve equal quarterly installments on the first day of each calendar quarter commencing July 1, 2016.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mineralys Therapeutics, Inc.
Report date August 10, 2026 · Filed August 12, 2026
Section 16 reporting ended · disclosed 2026-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,384 |
Ending reported balance
After 2026-08-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-10 · Exercise / conversion · Acquired 2,170 · Balance 53,554 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Row 2 · 2026-08-10 · Sale · Disposed 2,170 · Balance 51,384 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2033-02-09 | Direct | 13,024 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Exercise / conversion · Disposed 2,170 · Balance 13,024 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2: The stock option vests as to 25% of the total number of shares of Common Stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of Common Stock subject to the option on each monthly anniversary thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2025 Filed Apr 16, 2025 00:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001933414-25-000047 · wk-form4_1744763954.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:36 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 1,606 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · derivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,274 Underlying: Common Stock · 1,606 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:36 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 22,406 | $16.77 | $375,748.62 |
DisclosureSEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:36 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 2,791 | $16.02 | $44,717.12 |
DisclosureSEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,110 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.6434 to $16.2450. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:36 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 30,574 | $15.00 | $458,542.74 |
DisclosureSEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,901 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.50 to $15.48. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:36 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 1,606 | $1.08 | $1,734.48 |
DisclosureSEC source: 0001933414-25-000029 · wk-form4_1743716211.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 25, 2024. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 21:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000021 · wk-form4_1741900533.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,880 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 21:15 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-25-000021 · wk-form4_1741900533.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 24, 2025 23:59 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | GrantStock Option · Derivative | 170,000 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001933414-25-000019 · wk-form4_1740441576.xml · derivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2035-02-13 F1 · derivative.exercise_date: The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month anniversary following the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 22:29 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000010 · wk-form4_1739485768.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,229 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 22:29 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001933414-25-000010 · wk-form4_1739485768.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2025 Filed Jan 16, 2025 02:45 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,577 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 13, 2025 Filed Jan 16, 2025 02:45 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,018 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,018 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 13, 2025 Filed Jan 16, 2025 02:45 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2025 Filed Jan 16, 2025 02:45 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,018 | $0.54 | $2,709.72 |
DisclosureSEC source: 0001933414-25-000004 · wk-form4_1736995524.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance includes 797 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:37 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000062 · wk-form4_1734125816.xml · derivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,018 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 21:37 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000062 · wk-form4_1734125816.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,026 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · derivative · entry 5 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,926 Underlying: Common Stock · 5,026 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,035 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 5,026 | $15.00 | $75,398.04 |
DisclosureSEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · nonDerivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,991 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.05. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,026 | $1.08 | $5,428.08 |
DisclosureSEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:25 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:21 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 25,482 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000052 · wk-form4_1731100892.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,952 Underlying: Common Stock · 25,482 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:21 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 25,482 | $15.03 | $383,065.81 |
DisclosureSEC source: 0001933414-24-000052 · wk-form4_1731100892.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,974 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:21 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 25,482 | $1.08 | $27,520.56 |
DisclosureSEC source: 0001933414-24-000052 · wk-form4_1731100892.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 20:22 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,352 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,434 Underlying: Common Stock · 5,352 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 20:22 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,352 | $1.08 | $5,780.16 |
DisclosureSEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 20:22 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,052 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 20:22 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2024 Filed Sep 12, 2024 20:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,786 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 12, 2024 Filed Sep 12, 2024 20:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,018 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,069 Underlying: Common Stock · 5,018 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,018 | $0.54 | $2,709.72 |
DisclosureSEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,135 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,087 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,348 | $1.08 | $6,855.84 |
DisclosureSEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:20 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,890 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 22:34 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 525 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001628280-24-032253 · wk-form4_1721342039.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,483 Underlying: Common Stock · 525 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 22:34 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | SaleCommon Stock | 525 | $15.00 | $7,875.58 |
DisclosureSEC source: 0001628280-24-032253 · wk-form4_1721342039.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,873 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 22:34 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 525 | $1.08 | $567.00 |
DisclosureSEC source: 0001628280-24-032253 · wk-form4_1721342039.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023. Read SEC document |
| July 12, 2024 Filed Jul 12, 2024 20:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,008 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F5 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 12, 2024 Filed Jul 12, 2024 20:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 20:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,104 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 20:39 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This balance includes 1,778 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 21:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,349 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,357 Underlying: Common Stock · 6,349 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 21:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 6,349 | $1.08 | $6,856.92 |
DisclosureSEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · nonDerivative · entry 2 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,017 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,121 Underlying: Common Stock · 5,017 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:32 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionCommon Stock | 5,017 | $0.54 | $2,709.18 |
DisclosureSEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · nonDerivative · entry 1 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 6,348 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · derivative · entry 4 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,706 Underlying: Common Stock · 6,348 shares Expires 2032-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023. F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 13, 2024 Filed May 15, 2024 20:43 UTC | Mineralys Therapeutics, Inc. MLYS · Entity 4432 | Exercise / conversionStock Option · Derivative | 5,018 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001628280-24-023621 · wk-form4_1715805784.xml · derivative · entry 3 Rodman David Malcom · CIK 0001672659 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,138 Underlying: Common Stock · 5,018 shares Expires 2031-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023. F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.